| Literature DB >> 33101071 |
Jürgen Fuchshuber1,2, Jasmin Tatzer2,3, Michaela Hiebler-Ragger1,2, Florian Trinkl1,2, Andreas Kimmerle1,2, Anita Rinner2, Anna Buchheim4, Silke Schrom5, Beate Rinner5, Klaus Leber6, Thomas Pieber7, Elisabeth Weiss4, Andrew J Lewis8, Hans-Peter Kapfhammer1, Human Friedrich Unterrainer1,2,9.
Abstract
BACKGROUND: Substance use disorders (SUDs) have been described as a dysfunctional way to compensate for deficiencies in that person's underlying attachment system. Furthermore, the neuropeptide oxytocin (OT), which is a critical component of the neurobiology of the attachment system, has been shown to effectively reduce addictive behavior and therefore has been discussed as a potential medication in SUD treatment. This study investigates variation in peripheral OT plasma levels as a function of exposure to an attachment-related stimulus in SUD patients compared to healthy controls (HCs).Entities:
Keywords: maintenance treatment; attachment; oxytocin; poly drug use; substance use disorder
Year: 2020 PMID: 33101071 PMCID: PMC7544992 DOI: 10.3389/fpsyt.2020.460506
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Group differences in demographic data and conditions prior to investigation.
| PUD ( | HC ( | ||||||
|---|---|---|---|---|---|---|---|
| Age | 28.50 | 5.85 | 26.33 | 3.25 | -1.59 | 35.99 | 0.119 |
| Risk of substance use | |||||||
| Lifetime substance use (incl. alcohol & tobacco) | 23.63 | 4.79 | 8.63 | 4.18 | -11.56* | 45.17 | 0.000 |
| Global continuum of substance risk (incl. alcohol & tobacco) | 29.04 | 4.43 | 13.75 | 7.04 | -9.01 | 46 | 0.000 |
| Conditions day of examination | |||||||
| Waking up | 467.17 | 79.61 | 371.96 | 138.38 | -2.92* | 46 | 0.005 |
| Caffeine consumptiona | 440.63 | 178.57 | – | – | – | – | – |
| Nicotine consumptiona | 103.54 | 195.23 | – | – | – | – | – |
| Last meala | 272.63 | 133.84 | 360.04 | 256.75 | 1.48 | 34.64 | 0.146 |
| Sexual activity | 700.43 | 138.25 | 621.25 | 231.45 | -1.43 | 37.83 | 0.161 |
| Nationality | 7.54 | 4 | 0.110 | ||||
| Austria | 16 | 19 | |||||
| German language skills | 4.73 | 2 | 0.094 | ||||
| Mother tongue | 16 | 22 | |||||
| Education | 48.00* | 5 | 0.000 | ||||
| No completed Education | 1 | 0 | |||||
| Psychiatric diagnosis | 45.15* | 1 | 0.000 | ||||
| Yes | 24 | 0 | |||||
| Current psychotherapy | 49.00* | 1 | 0.000 | ||||
| Yes | 24 | 0 | |||||
| Chronic physical health problems | 3.33 | 1 | 0.068 | ||||
| Yes | 3 | 0 | |||||
| Regular medication | 49.00* | 1 | 0.020 | ||||
| Yes | 24 | 0 | |||||
*p < 0.05; PUD, Poly-drug use disordered patients; HC, Healthy controls. aPast time in minutes since last consumption on test day.
Group differences (ANOVA) in behavioral and biological measures.
| Measures | PUD ( | HC ( | ||||||
|---|---|---|---|---|---|---|---|---|
| BSI-18 | ||||||||
| Somatization | 0.690 | 2.17 | 2.73 | 2.13 | 2.35 | 0.00 | 0.00 | 0.955 |
| Depression | 0.852 | 6.25 | 5.57 | 2.71 | 2.33 | 8.27* | 0.15 | 0.006 |
| Anxiety | 0.816 | 4.54 | 5.01 | 3.46 | 2.41 | 0.91 | 0.02 | 0.344 |
| Total Score | 0.869 | 12.96 | 11.14 | 8.71 | 5.39 | 2.83 | 0.06 | 0.099 |
| Oxytocin | ||||||||
| Pre (pg/ml) | 60.64 | 24.87 | 44.74 | 15.68 | 7.02* | 0.13 | 0.011 | |
| Post (pg/ml) | 60.38 | 17.25 | 60.46 | 38.73 | 0.00 | 0.00 | 0.992 | |
| Reactivity | -0.26 | 17.64 | 15.72 | 39.66 | 3.25 | 0.06 | 0.078 | |
| AAS | ||||||||
| Dependence | 0.731 | 16.13 | 4.89 | 18.42 | 3.31 | 3.61 | 0.07 | 0.064 |
| Closeness | 0.786 | 11.63 | 3.93 | 13.92 | 4.03 | 3.97 | 0.08 | 0.052 |
| Anxiety | 0.678 | 12.29 | 3.91 | 12.29 | 3.75 | 0.00 | 0.00 | 1.000 |
Bonferroni corrected p = 0.005; *p < 0.05; PUD, Poly-drug use disordered patients; HC, Healthy controls; Pre, baseline OT-levels; Post, OT-levels after confrontation with attachment related cue.
Intercorrelations for behavioral and biological measures for PUD (n = 24).
| Variable | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. BSI-18 Somatization | .40 | .79** | −.21 | −.03 | .27 | −.11 | −.15 | .19 | .17 | .14 | |
| 2. BSI-18 Depression | .48* | −.04 | .01 | .06 | −.51* | −.46* | .49* | .21 | .21 | ||
| 3. BSI-18 Anxiety | −.13 | −.08 | .10 | −.02 | −.12 | .22 | .14 | .34 | |||
| 4. OT Pre | .70** | −.72* | .05 | −.41 | −.37 | −.48* | .11 | ||||
| 5. OT Post | −.02 | .07 | −.24 | −.33 | −.31 | −.04 | |||||
| 6. OT Reactivity | .00 | .34 | .20 | .37 | −.19 | ||||||
| 7. AAS Dependence | .68** | −.36 | −.05 | −.20 | |||||||
| 8. AAS Closeness | −.02 | −.04 | −.22 | ||||||||
| 9. AAS Anxiety | −.18 | .24 | |||||||||
| 10. ASSIST Lifetime SU | −.16 | ||||||||||
| 11. ASSIST GC of SR |
N = 24; Bonferroni corrected p = 0.004; **p < .01, *p < .05; Pre, baseline OT-levels; Post, OT-levels after confrontation with attachment related cue; GC, global continuum; SU, substance use; SR, substance risk.